Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients With Mild-Moderate COVID-19

Next Previous
X
Search
Trial Profile

Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients With Mild-Moderate COVID-19

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 Feb 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bucillamine (Primary)
  • Indications COVID-19 respiratory infection
  • Focus Registrational; Therapeutic Use
  • Sponsors Revive Therapeutics

    • Most Recent Events

    • 01 Feb 2024 According to Revive Therapeutics media release, company aims to linical development of Bucillamine by leveraging the published research and existing data from its previous Phase 3 clinical trial to the FDA and international health regulatory bodies.
    • 06 Jul 2023 Results published in the Revive Therapeutics Media Release
    • 20 Jun 2023 Status changed from recruiting to discontinued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top